You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]

  • Awaiting development
  • Reference number: GID-TA12518
  • Expected publication date: TBC
  • Project information
  • Project documents

Documents

Documents created during the development process.

Notes

  • This is the deferred appraisal of D5. Scoping documents can be found on the record for D5. The appraisal is expected to begin in early July 2026.

Back to top